المؤلفون: Seijas-Tamayo, R., Fernández-Mateos, J., Adansa Klain, J. C., Mesía, R., Pastor Borgoñón, M., Pérez-Ruiz, E., Vázquez Fernández, S., Salvador Coloma, C., Rueda Domínguez, A., Taberna, M., Martínez-Trufero, J., Bonfill Abella, T., Vázquez Estévez, S., Pollán, M., del Barco Morillo, E., Cruz-Hernández, J. J.

المصدر: Clinical and Translational Oncology. November 2016 18(11):1114-1122

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Fernández-Mateos J; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain; Molecular Medicine Unit-IBSAL, Department of Medicine, University of Salamanca, Spain; Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain., Seijas-Tamayo R; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain., Mesía R; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet de Llobregat, Barcelona, Spain., Taberna M; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet de Llobregat, Barcelona, Spain., Pastor Borgoñón M; Medical Oncology Service, Hospital Universitario Politécnico La Fe, Valencia, Spain., Pérez-Ruiz E; Division of Medical Oncology, Oncology Department, Hospital Costa del Sol, Marbella, Spain., Adansa Klain JC; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain., Vázquez Fernández S; Medical Oncology Department, Institut Català d'Oncologia L'Hospitalet de Llobregat, Barcelona, Spain., Del Barco Morillo E; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain., Lozano A; Radiation Oncology Department, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain., González Sarmiento R; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain; Molecular Medicine Unit-IBSAL, Department of Medicine, University of Salamanca, Spain; Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain. Electronic address: gonzalez@usal.es., Cruz-Hernández JJ; Medical Oncology Service, University Hospital of Salamanca-IBSAL, Salamanca, Spain; Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, Salamanca, Spain; Molecular Medicine Unit-IBSAL, Department of Medicine, University of Salamanca, Spain. Electronic address: ttcc@seom.org.

مؤلفون مشاركون: Spanish Head and Neck Cancer Cooperative Group (TTCC)

المصدر: Oral oncology [Oral Oncol] 2016 Dec; Vol. 63, pp. 38-43. Date of Electronic Publication: 2016 Nov 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Polymorphism, Genetic*, Antineoplastic Agents, Immunological/*adverse effects , Carcinoma, Squamous Cell/*drug therapy , Cetuximab/*adverse effects , ErbB Receptors/*genetics , Head and Neck Neoplasms/*drug therapy, Antineoplastic Agents, Immunological/therapeutic use ; Cetuximab/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Spain ; Squamous Cell Carcinoma of Head and Neck